González-Macías J, Del Pino-Montes J, Olmos J M, Nogués X
Departamento de Medicina Interna, Hospital Universitario Marqués de Valdecilla. IDIVAL, Red Temática de Investigación Cooperativa en Envejecimiento y Fragilidad (RETICEF), Universidad de Cantabria, Santander, España.
Servicio de Reumatología, Red Temática de Investigación Cooperativa en Envejecimiento y Fragilidad RETICEF), Universidad de Salamanca, Alfonso X el Sabio, Salamanca, España.
Rev Clin Esp (Barc). 2015 Dec;215(9):515-26. doi: 10.1016/j.rce.2015.08.003. Epub 2015 Oct 4.
These guidelines update issues covered in previous versions and introduce new ones that have arisen in recent years. The former refer mainly to the therapeutic developments that have been made during this time (zoledronate, denosumab, bazedoxifene), which have led to a change in the drug selection algorithm. The latter deal with therapeutic management, the description of new adverse effects (which have led to changes in therapeutic behaviour patterns, as is the case with atypical fracture of the femur), treatment duration (with consideration for the so-called "therapeutic holidays"), the so-called sequential treatment and changes in treatment imposed by certain circumstances. A new algorithm has been introduced for sequential treatment. Attention has also been paid to vertebroplasty and kyphoplasty.
本指南更新了先前版本中涵盖的问题,并引入了近年来出现的新问题。前者主要涉及在此期间取得的治疗进展(唑来膦酸、地诺单抗、巴多昔芬),这些进展导致了药物选择算法的改变。后者涉及治疗管理、新不良反应的描述(这些不良反应导致了治疗行为模式的改变,如股骨非典型骨折)、治疗持续时间(考虑所谓的“治疗假期”)、所谓的序贯治疗以及某些情况导致的治疗变化。已引入一种新的序贯治疗算法。同时也关注了椎体成形术和后凸成形术。